Cargando…

Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India

OBJECTIVE: To assess effectiveness and safety of a generic fixed-dose combination of tenofovir (TDF)/emtricitabine (FTC)/efavirenz (EFV) among HIV-1-infected patients in Western India. METHODS: Antiretroviral (ARV)-naive and experienced (thymidine analog nucleoside reverse transcriptase inhibitor [t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pujari, Sanjay, Dravid, Ameet, Gupte, Nikhil, Joshix, Kedar, Bele, Vivek
Formato:	Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757396/ https://www.ncbi.nlm.nih.gov/pubmed/19825144 http://dx.doi.org/10.1186/1758-2652-10-8-196

Ejemplares similares

Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
por: Patil, Rashmee, et al.
Publicado: (2015)

Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: A comparative cohort analysis between Western India and United Kingdom
por: Pujari, Sanjay N, et al.
Publicado: (2014)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
por: Lamorde, Mohammed, et al.
Publicado: (2012)

Long‐coronavirus disease among people living with HIV in western India: An observational study
por: Pujari, Sanjay, et al.
Publicado: (2021)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats
por: Everson, Frans, et al.
Publicado: (2018)

Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
por: Pohlman, F Will, et al.
Publicado: (2021)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals
por: Moyle, Graeme J., et al.
Publicado: (2015)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

537 STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
por: Creticos, Catherine, et al.
Publicado: (2014)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
por: Peng, Yongquan, et al.
Publicado: (2023)

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
por: Jing, Cao, et al.
Publicado: (2023)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
por: Feng, Joy Y, et al.
Publicado: (2009)

Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
por: Xia, Huan, et al.
Publicado: (2021)

Eosinophilic Colitis Associated with Emtricitabine/Tenofovir
por: Lozier, Matthew R, et al.
Publicado: (2018)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
por: Stirrup, Oliver T, et al.
Publicado: (2019)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2018)

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
por: Hill, Lucas, et al.
Publicado: (2018)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2019)

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients
por: Aloysius, Isaac, et al.
Publicado: (2017)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis—Maraviroc Effectiveness in HIV-1 Subtype C
por: Pujari, Sanjay, et al.
Publicado: (2018)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2 )vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
por: Focà, Emanuele, et al.
Publicado: (2012)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates
por: Chen, Xinhui, et al.
Publicado: (2016)

Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women
por: Tanaudommongkon, Asama, et al.
Publicado: (2022)

Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
por: Dravid, Ameet, et al.
Publicado: (2022)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
por: Ranzenigo, Martina, et al.
Publicado: (2022)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Vitamin D and Calcium Supplement Attenuate Bone Loss among HIV-Infected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial
por: Boontanondha, Patawee, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mt08jbhse3ghas2s433pl0p7hk